Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Takeda Pharmaceutical CO Ltd. (TAK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 30,669,126
  • Shares Outstanding, K 1,562,360
  • Annual Sales, $ 15,935 M
  • Annual Income, $ 1,682 M
  • 36-Month Beta 0.54
  • Price/Sales 1.92
  • Price/Cash Flow 8.89
  • Price/Book 1.61

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year 0.39
  • Growth Rate Est. (year over year) +256,053.85%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.81 +25.11%
on 12/19/18
20.17 -1.93%
on 01/11/19
+4.14 (+26.47%)
since 12/18/18
3-Month
15.50 +27.61%
on 12/18/18
21.15 -6.48%
on 10/31/18
-0.88 (-4.26%)
since 10/18/18
52-Week
15.50 +27.61%
on 12/18/18
31.29 -36.78%
on 02/01/18
-9.27 (-31.92%)
since 01/18/18

Most Recent Stories

More News
Ironwood to Get New CEO, Current CEO to Head Latest Spinoff

Ironwood Pharma (IRWD) appoints AstraZeneca executive, Mark Mellon, as its new chief executive officer. Peter Hecht, the current CEO, will lead the new spinoff company focusing on rare disease.

IRWD : 12.91 (-1.53%)
AZN : 36.55 (+0.72%)
AGN : 160.22 (+2.34%)
TAK : 19.78 (+0.76%)
CORRECTING and REPLACING The NYSE Welcomes 2019 as the Global Leader in Listings

--Each of the last 25 consecutive U.S. IPOs raising $1 billion or more listed on the NYSE;

BE : 12.67 (-3.36%)
REZI : 21.80 (-0.46%)
CDAY : 38.23 (+2.25%)
BJ : 24.60 (+0.61%)
VNE : 32.79 (+7.58%)
NTR : 51.29 (+0.57%)
NVT : 24.66 (+2.32%)
FPAC : 9.75 (+0.10%)
ADT : 7.33 (+0.96%)
WH : 49.98 (+1.75%)
FTCH : 20.87 (+4.25%)
HUD : 13.64 (+4.12%)
QGEN : 36.93 (+0.79%)
PVTL : 17.14 (+2.82%)
EQH : 18.88 (-0.63%)
EB : 31.18 (+1.80%)
DELL : 43.35 (-0.82%)
CCC : 10.44 (+1.95%)
SPOT : 133.66 (+0.31%)
SWI : 16.90 (+2.18%)
YETI : 18.08 (-0.06%)
ARLO : 7.54 (-4.31%)
ICE : 75.63 (+1.04%)
SPAQ : 9.70 (+0.10%)
AMRX : 12.42 (-0.56%)
SMAR : 28.59 (+3.77%)
TME : 14.35 (+10.64%)
LTHM : 13.06 (+0.46%)
LIN : 160.79 (+2.24%)
VICI : 21.11 (+0.57%)
GSAH : 9.85 (unch)
ELAN : 31.52 (-0.72%)
RAMP : 43.06 (+1.92%)
ZUO : 21.14 (+1.83%)
HUYA : 20.31 (+3.04%)
PAGS : 22.39 (+5.41%)
SUZ : 23.60 (+2.70%)
TAK : 19.78 (+0.76%)
The NYSE Welcomes 2019 as the Global Leader in Listings

--Each of the last 25 consecutive U.S. IPOs raising $1 billion or more listed on the NYSE;

BE : 12.67 (-3.36%)
REZI : 21.80 (-0.46%)
CDAY : 38.23 (+2.25%)
BJ : 24.60 (+0.61%)
VNE : 32.79 (+7.58%)
NTR : 51.29 (+0.57%)
NVT : 24.66 (+2.32%)
FPAC : 9.75 (+0.10%)
ADT : 7.33 (+0.96%)
WH : 49.98 (+1.75%)
FTCH : 20.87 (+4.25%)
HUD : 13.64 (+4.12%)
QGEN : 36.93 (+0.79%)
PVTL : 17.14 (+2.82%)
EB : 31.18 (+1.80%)
DELL : 43.35 (-0.82%)
CCC : 10.44 (+1.95%)
SPOT : 133.66 (+0.31%)
SWI : 16.90 (+2.18%)
YETI : 18.08 (-0.06%)
ARLO : 7.54 (-4.31%)
ICE : 75.63 (+1.04%)
SPAQ : 9.70 (+0.10%)
AMRX : 12.42 (-0.56%)
SMAR : 28.59 (+3.77%)
TME : 14.35 (+10.64%)
LTHM : 13.06 (+0.46%)
LIN : 160.79 (+2.24%)
VICI : 21.11 (+0.57%)
GSAH : 9.85 (unch)
ELAN : 31.52 (-0.72%)
RAMP : 43.06 (+1.92%)
ZUO : 21.14 (+1.83%)
HUYA : 20.31 (+3.04%)
PAGS : 22.39 (+5.41%)
SUZ : 23.60 (+2.70%)
TAK : 19.78 (+0.76%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade TAK with:

Business Summary

Takeda Pharmaceutical Company Limited operates as a research-based pharmaceutical company, engaged in manufacturing, marketing, and importing/exporting pharmaceutical drugs. Takeda's core business comprise of ethical drugs and its portfolio includes lansoprazole for the treatment of peptic ulcers, leuprolide...

See More

Key Turning Points

2nd Resistance Point 20.02
1st Resistance Point 19.90
Last Price 19.78
1st Support Level 19.62
2nd Support Level 19.46

See More

52-Week High 31.29
Fibonacci 61.8% 25.26
Fibonacci 50% 23.40
Fibonacci 38.2% 21.53
Last Price 19.78
52-Week Low 15.50

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar